Cancer

Oncology
141
Pipeline Programs
30
Companies
50
Clinical Trials
1 recruiting
9
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
75
11
35
0
9
11
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1761%
Monoclonal Antibody
1036%
Vaccine
14%
+ 144 programs with unclassified modality

On Market (9)

Approved therapies currently available

U
BILDYOSApproved
denosumab
Unknown Company
RANK Ligand Inhibitor [EPC]injection2025
U
BILPREVDAApproved
denosumab
Unknown Company
RANK Ligand Inhibitor [EPC]injection2025
Swedish Orphan Biovitrum
KEPIVANCEApproved
palifermin
Swedish Orphan Biovitrum
Mucocutaneous Epithelial Cell Growth Factor [EPC]injection2004
Amgen
NEULASTAApproved
pegfilgrastim
Amgen
2002
Amgen
PROLIAApproved
denosumab
Amgen
RANK Ligand Inhibitor [EPC]subcutaneous2010
Novartis
TAFINLARApproved
dabrafenib
Novartis
oral2023
Roche
TECENTRIQApproved
atezolizumab
Roche
Programmed Death Receptor-1 Blocking Antibody [EPC]injection2016
Roche
TECENTRIQ HYBREZAApproved
atezolizumab and hyaluronidase-tqjs
Roche
Programmed Death Receptor-1 Blocking Antibody [EPC]injection2024
Amgen
XGEVAApproved
denosumab
Amgen
RANK Ligand Inhibitor [EPC]subcutaneous2010

Competitive Landscape

61 companies ranked by most advanced pipeline stage

Amgen
10 programs
4
3
2
1
PegfilgrastimPhase 31 trial
rHuEPOPhase 31 trial
DenosumabPhase 2Monoclonal Antibody1 trial
PanitumumabPhase 2Monoclonal Antibody
PanitumumabPhase 2Monoclonal Antibody1 trial
+5 more programs
Active Trials
NCT00300001Unknown300
NCT00770536Completed103Est. Jun 2015
NCT00813384Completed54Est. Dec 2014
+6 more trials
Novartis
NovartisBASEL, Switzerland
10 programs
4
3
1
TAFINLAR(Dabrafenib)Phase 2Small Molecule1 trial
GSK1120212Phase 23 trials
GSK2110183Phase 22 trials
AEE788Phase 11 trial
AfuresertibPhase 1Small Molecule
+5 more programs
Active Trials
NCT01332396Completed4,054Est. Mar 2017
NCT01376115Completed343Est. Oct 2017
NCT00487123CompletedEst. Sep 2007
+13 more trials
Pfizer
5 programs
4
1
dalteparinPhase 41 trial
ARRY-380, HER2 inhibitor; oralPhase 11 trial
Cofetuzumab PelidotinPhase 11 trial
European Taxotere®Phase 11 trial
PF-04691502Phase 11 trial
Active Trials
NCT00650572Completed50Est. Mar 2013
NCT04189614Active Not Recruiting65Est. Dec 2025
NCT01268163Completed32Est. Dec 2008
+2 more trials
Astellas
AstellasChina - Shenyang
3 programs
1
1
1
ramosetron, aprepitant, dexamethasonePhase 41 trial
ramosetronPhase 31 trial
YM155Phase 11 trial
Active Trials
NCT01023386Completed6Est. Mar 2010
NCT01536691Unknown338Est. Feb 2013
NCT02532634Completed292Est. May 2018
Roche
RocheSTAVANGER NORWAY, Norway
1 program
1
1
TECENTRIQ HYBREZA(Atezolizumab)Phase 3Monoclonal Antibody1 trial
Active Trials
NCT03768063Active Not Recruiting1,000Est. Jul 2028
Swedish Orphan Biovitrum
1
1
paliferminPhase 3
Alliance Pharmaceuticals
1
glutaminePhase 31 trial
Cancer Treatment OptionsN/A1 trial
Community Health Worker SupportN/A
IMPROVED interventionN/A1 trial
MifepristoneN/A1 trial
+2 more programs
Active Trials
NCT02105545Completed250Est. Apr 2023
NCT03396510Completed390Est. Dec 2022
NCT00832871Terminated4Est. Dec 2015
+3 more trials
Sanofi
4 programs
3
1
XRP6976Phase 31 trial
XL147Phase 11 trial
XL147Phase 11 trial
XL765Phase 13 trials
Active Trials
NCT00756847Completed52Est. Oct 2012
NCT00692640Completed35Est. Nov 2011
NCT00777699Completed80Est. Feb 2011
+3 more trials
Bayer
2 programs
1
dexpanthenol 5% creamPhase 31 trial
Cancer treatment with tyrosine kinase inhibitorsN/A
Active Trials
NCT01136005Completed160Est. Mar 2017
DS
1
DenosumabPhase 3Monoclonal Antibody
E
16 programs
12
3
EribulinPhase 21 trial
LenvatinibPhase 2Small Molecule1 trial
PanitumumabPhase 2Monoclonal Antibody
E7050Phase 11 trial
E7070 + irinotecan combinationPhase 11 trial
+11 more programs
Active Trials
NCT01432483No Longer Available
NCT00869895Completed60
NCT00060567Completed88Est. Mar 2013
+12 more trials
M&
Merck & Co.RAHWAY, NJ
15 programs
7
1
2
ARQ 501Phase 21 trial
alvimopanPhase 25 trials
ARQ 501Phase 1/21 trial
ARQ 171Phase 11 trial
ARQ 197Phase 11 trial
+10 more programs
Active Trials
NCT06326567Recruiting300Est. Dec 2027
NCT04726020Completed645Est. Jan 2022
NCT03245411Recruiting110Est. Dec 2025
+16 more trials
AstraZeneca
8 programs
5
2
CediranibPhase 2Small Molecule1 trial
Durvalumab InjectionPhase 21 trial
AZD8055Phase 11 trial
AZD8055Phase 11 trial
AZD8055Phase 11 trial
+3 more programs
Active Trials
NCT01194193Withdrawn63
NCT00999882Completed26Est. Dec 2011
NCT00973076Completed19Est. Dec 2010
+4 more trials
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
6 programs
2
3
AbemaciclibPhase 2Small Molecule1 trial
BevacizumabPhase 2Monoclonal Antibody1 trial
IMC-1121BPhase 23 trials
IC83/LY2603618Phase 11 trial
IMC-RON8Phase 11 trial
+1 more programs
Active Trials
NCT02632994Available
NCT00415636Completed31Est. Jul 2010
NCT01119456Completed39Est. Nov 2013
+5 more trials
Teva
5 programs
2
2
ACTIQ®Phase 21 trial
inhaled delta-8-THC 300mcg or 600mcg per dosePhase 21 trial
CEP-11981Phase 11 trial
Custirsen, paclitaxel and carboplatinPhase 11 trial
Effentora®N/A1 trial
Active Trials
NCT01400854Completed600Est. Oct 2012
NCT00875264Completed43Est. Jun 2011
NCT01497470Completed36Est. Oct 2013
+2 more trials
Novo Nordisk
4 programs
4
recombinant interleukin-21Phase 21 trial
recombinant interleukin-21Phase 21 trial
recombinant interleukin-21Phase 21 trial
recombinant interleukin-21Phase 21 trial
Active Trials
NCT00617253Completed9Est. Jun 2008
NCT00336986Completed54Est. Oct 2007
NCT00601861Terminated1Est. Jun 2008
+1 more trials
Genentech
3 programs
1
1
BevacizumabPhase 2Monoclonal Antibody
5-FUPhase 11 trial
'My Care Plan'N/A1 trial
Active Trials
NCT02405819Completed41Est. Feb 2016
NCT01633970Completed240Est. Feb 2020
CT
2
1
AnlotinibPhase 2Small Molecule1 trial
AnlotinibPhase 1Small Molecule1 trial
TQ-B3203Phase 11 trial
Active Trials
NCT02752516UnknownEst. Dec 2017
NCT03447145UnknownEst. Dec 2018
NCT01878448CompletedEst. Apr 2017
AbbVie
2 programs
1
1
LeucovorinPhase 21 trial
Cofetuzumab PelidotinPhase 1
Active Trials
NCT03368859Terminated70Est. Dec 2019
Ipsen
IpsenChina - Tianjin
2 programs
2
PanitumumabPhase 2Monoclonal Antibody
combination of Avelumab and CabozantinibPhase 2Small Molecule
GS
2 programs
2
lorlatinibPhase 2Small Molecule1 trial
lorlatinibPhase 2Small Molecule
Active Trials
NCT05097599Terminated11Est. Jun 2024
AT
Actuate TherapeuticsFORT WORTH, TX
1 program
1
9-ING-41Phase 21 trial
Active Trials
NCT03678883Active Not RecruitingEst. Jan 2026
Lassen Therapeutics
Lassen TherapeuticsCA - San Diego
1 program
1
AlectinibPhase 2Small Molecule1 trial
Active Trials
NCT04341181Recruiting300Est. Apr 2030
OD
1 program
1
Epoetin alfaPhase 2
Qilu Pharmaceutical
Qilu PharmaceuticalChina - Jinan
1 program
1
Iparomlimab and Tuvonralimab InjectionPhase 21 trial
Active Trials
NCT07041788Not Yet RecruitingEst. Jul 2030
Boehringer Ingelheim
1
PanitumumabPhase 2Monoclonal Antibody
Delcath
1 program
1
isolated perfusionPhase 21 trial
Active Trials
NCT00096083Completed56Est. Aug 2012
Bristol Myers Squibb
11 programs
5
4
BMS-911543Phase 1/21 trial
BMS-986253Phase 1/22 trials
BMS-986277Phase 1/21 trial
celecoxibPhase 1/2Small Molecule1 trial
BMS-833923Phase 11 trial
+6 more programs
Active Trials
NCT04513678Completed64Est. Dec 2021
NCT06163053Completed49Est. Jun 2025
NCT01413906Completed12Est. Nov 2012
+9 more trials
Jazz Pharmaceuticals
2
SativexPhase 1/21 trial
SativexPhase 1/21 trial
Active Trials
NCT01812603Completed6Est. Jun 2016
NCT01812616Completed21Est. Jun 2016
Philogen
PhilogenItaly - Monteriggioni
1 program
1
131I-F16SIP RadioimmunotherapyPhase 1/21 trial
Active Trials
NCT01240720Completed65Est. Apr 2013

+31 more companies

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
NovartisTreatment
NovartisTreatment
NovartisTreatment
NovartisTreatment
NovartisTreatment
NovartisTreatment
Astellasramosetron, aprepitant, dexamethasone
NovartisTreatment
NovartisTreatment
NovartisTreatment
NovartisTreatment
NovartisTreatment
NovartisTreatment
NovartisTreatment
NovartisTreatment

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 33,338 patients across 50 trials

Efficacy of the New Closure Device in Improving Patient Compliance in Treatment of Hypertension With Valsartan+/-Hydrochlorothiazide (HCTZ) at 6 Months

Est. completion: Sep 2007
Phase 4Completed

A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation

Start: Mar 2022Est. completion: Mar 2027136 patients
Phase 4Active Not Recruiting

Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls.

Start: Jan 2022Est. completion: Feb 2026180 patients
Phase 4Completed

A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod

Start: Sep 2017Est. completion: Jun 2019382 patients
Phase 4Completed

Pasireotide Treatment for Neuroendocrine Tumor

Start: Apr 2016Est. completion: Jun 20160
Phase 4Withdrawn

Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study

Start: Dec 2015Est. completion: Jun 2027233 patients
Phase 4Active Not Recruiting
NCT02532634Astellasramosetron, aprepitant, dexamethasone

Ramosetron, Aprepitant, and Dexamethasone Versus Palonosetron, Aprepitant, and Dexamethasone

Start: Aug 2015Est. completion: May 2018292 patients
Phase 4Completed

Effect of an Individualized Patient Support Program on Treatment Satisfaction in Fingolimod-treated Patients With RRMS

Start: Jul 2013Est. completion: Jul 20130
Phase 4Withdrawn

Safety and Efficacy of Vildagliptin Plus Metformin (SPC) Treatment in Type 2 Diabetes Mellitus Patients

Start: Apr 2013Est. completion: Sep 201540 patients
Phase 4Completed

Triple Treatment for Detachment of Retinal Pigment Epithelium Secondary to Polypoidal Choroidal Vasculopathy

Start: Sep 2012Est. completion: Sep 20140
Phase 4Withdrawn

A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya®

Start: Aug 2012Est. completion: Feb 201987 patients
Phase 4Completed

Double-dose Valsartan Monotherapy in Hypertension Treatment: an Effectiveness and Safety Evaluation in Chinese Patients.

Start: Feb 2012Est. completion: Jan 2013200 patients
Phase 4Completed

RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation

Start: Apr 2011Est. completion: Mar 201549 patients
Phase 4Completed

Efficacy of Diclofenac Potassium vs Nimesulide in the Treatment of Fever and Pain in Children With Upper Respiratory Tract Infection

Start: Apr 20110
Phase 4Withdrawn

Biomarker Study After Initiation of Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis

Start: Feb 2011Est. completion: Jul 2012447 patients
Phase 4Completed

A Community Setting Study of Malaria After Systematic Treatment of Symptomatic Carriers of P. Falciparum With COA566 (Coartem®)

Start: Nov 2010Est. completion: Jul 201214,075 patients
Phase 4Completed

The Effect of Vildagliptin Based Treatment Versus Sulfonylurea on Glycemic Variability, Oxidative Stress, GLP-1, and Endothelial Function in Patients With Type 2 Diabetes

Start: Jun 2010Est. completion: May 201234 patients
Phase 4Completed

Multicenter, Randomized, Open-label Study to Assess Whether Treatment With Mycophenolate Sodium (MPS) Allows Higher Dose Optimization Versus Mycophenolate Mofetil (MMF) Leading to a Dose Reduction of Tacrolimus. Maximiza Study.

Start: May 2010Est. completion: Apr 201389 patients
Phase 4Completed

Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C

Start: Sep 2009Est. completion: May 201392 patients
Phase 4Completed

Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer

Start: Jun 2009Est. completion: Jun 2013338 patients
Phase 4Completed

GenTeal in Perioperative Treatment of Laser Assisted in Situ Keratomileusis LASIK Patients

Start: Oct 2007Est. completion: Oct 200980 patients
Phase 4Completed

Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin-structure Infections

Start: Jan 200752 patients
Phase 4Terminated

Patient's Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder

Start: Jun 2006Est. completion: Sep 2007500 patients
Phase 4Completed

Study to Compare the Effect of Treatment With Carbidopa/Levodopa/Entacapone on the Quality of Life of Patients With Parkinson's Disease. This Study is Not Recruiting in the United States

Start: Jul 2005Est. completion: Jun 2006184 patients
Phase 4Completed

Open Label Extension Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder

Start: Dec 2004Est. completion: Jul 2007181 patients
Phase 4Completed

Comparison of Two Treatment Strategies in Hypertensive Patients

Start: Jun 2004Est. completion: May 20054,445 patients
Phase 4Completed

Study of the Effects of Current Drug Treatments on Levels of Certain Brain Chemicals in Alzheimer's Disease

Start: Oct 2003Est. completion: Apr 200680 patients
Phase 4Completed

A Study to Evaluate the Safety and Efficacy of Single Day or Single Dose Famciclovir for the Treatment of Recurrent Herpes Labialis

Start: Oct 2003Est. completion: Jul 2007
Phase 4Completed

The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Adolescents With Impulsivity and Aggressive Behavior in Conduct Disorder This Study is Not Being Conducted in the United States.

Start: Apr 2003Est. completion: Oct 200450 patients
Phase 4Completed

The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Bipolar Disorder I or II This Study is Not Being Conducted in the United States.

Start: Jan 2003Est. completion: Jan 200655 patients
Phase 4Completed

Preoperative Octreotide Treatment of Acromegaly

Start: Sep 1999Est. completion: May 201062 patients
Phase 4Completed

A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer

Start: Jun 2024Est. completion: Mar 20323,360 patients
Phase 3Recruiting

Phase IIIb, Open-label, Multi-center Study to Evaluate Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally to Participants With SMA Who Discontinued Treatment With Nusinersen or Risdiplam

Start: Jan 2023Est. completion: Nov 202427 patients
Phase 3Completed

A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE

Start: Sep 2022Est. completion: Feb 2027417 patients
Phase 3Active Not Recruiting

A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE

Start: May 2022Est. completion: Feb 20261,150 patients
Phase 3Terminated

Asciminib Treatment Optimization in ≥ 3rd Line CML-CP

Start: Oct 2021Est. completion: Feb 2026199 patients
Phase 3Active Not Recruiting

177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer

Start: Jun 2021Est. completion: Sep 2026469 patients
Phase 3Active Not Recruiting

Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment

Start: Jan 2021Est. completion: Mar 202397 patients
Phase 3Completed

An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab

Start: Jul 2020Est. completion: Mar 2025562 patients
Phase 3Completed

A Safety and Efficacy Study of Ligelizumab in the Treatment of CSU in Japanese Patients Inadequately Controlled With H1- Antihistamines

Start: Apr 2019Est. completion: Jan 202266 patients
Phase 3Completed
NCT03768063RocheAtezolizumab

A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

Start: Feb 2019Est. completion: Jul 20281,000 patients
Phase 3Active Not Recruiting

Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes

Start: Aug 2018Est. completion: Sep 2021552 patients
Phase 3Completed

Alvimopan as Rescue in Post op Ileus

Start: Dec 2015Est. completion: Jul 201814 patients
Phase 3Terminated

Safety and Tolerability During Open-label Treatment With LCZ696 in Patients With CHF and Reduced Ejection Fraction

Start: Oct 2014Est. completion: Dec 20171,980 patients
Phase 3Completed

A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD

Start: Dec 2013Est. completion: Sep 20140
Phase 3Withdrawn

A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD

Start: Dec 2013Est. completion: Sep 20140
Phase 3Withdrawn

3-year Follow-up Study to Assess the Viral Activity in Hepatitis C Patients Who Failed Feeder DEB025/Alisporivir Study

Start: Sep 2012Est. completion: Jan 2014105 patients
Phase 3Terminated

Daptomycin Versus Vancomycin in the Treatment of Nosocomial or Healthcare-associated MRSA Bacteremia

Start: May 2012Est. completion: Jul 201410 patients
Phase 3Terminated

GP2013 in the Treatment of Patients With Previously Untreated, Advanced Stage Follicular Lymphoma (ASSIST_FL)

Start: Dec 2011Est. completion: Jan 2018629 patients
Phase 3Completed

Ramosetron, Aprepitant and Dexamethasone Versus Ondansetron, Aprepitant and Dexamethasone

Start: Jun 2011Est. completion: Feb 2013338 patients
Phase 3Unknown

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

9 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 33,338 patients
30 companies competing in this space